Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Hana Florian"'
Autor:
Edward F. Greenberg, Martin J. Voorbach, Alexandra Smith, David R. Reuter, Yuchuan Zhuang, Ji-Quan Wang, Dustin W. Wooten, Elizabeth Asque, Min Hu, Carolin Hoft, Ryan Duggan, Matthew Townsend, Karin Orsi, Karen Dalecki, Willi Amberg, Lori Duggan, Heather Knight, Joseph S. Spina, Yupeng He, Kennan Marsh, Vivian Zhao, Suzanne Ybarra, Jennifer Mollon, Yuni Fang, Aparna Vasanthakumar, Susan Westmoreland, Mathias Droescher, Sjoerd J. Finnema, Hana Florian
Publikováno v:
Heliyon, Vol 10, Iss 16, Pp e36483- (2024)
Alzheimer's disease (AD) is the most common global dementia and is universally fatal. Most late-stage AD disease-modifying therapies are intravenous and target amyloid beta (Aβ), with only modest effects on disease progression: there remains a high
Externí odkaz:
https://doaj.org/article/503b4807cc8c4b5188138ba8175721c8
Autor:
Ronald C. Petersen, Ana Graf, Chris Brady, Susan De Santi, Hana Florian, Jaren Landen, Mike Pontecorvo, Christopher Randolph, Kaycee M. Sink, Maria C. Carrillo, Christopher J. Weber
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 4, Pp n/a-n/a (2023)
Abstract Alzheimer's disease (AD) staging criteria lack standardized, empirical description. Well‐defined AD staging criteria are an important consideration in protocol design, influencing a more standardized inclusion/exclusion criteria and defini
Externí odkaz:
https://doaj.org/article/3165a19f6e46401bb79c035cd29ef3bd
Autor:
Hana Florian, Deli Wang, Steven E Arnold, Mercè Boada, Qi Guo, Ziyi Jin, Hui Zheng, Nahome Fisseha, Hari Varun Kalluri, Beatrice Rendenbach-Mueller, Kumar Budur, Michael Gold
Publikováno v:
Brain. 146:2275-2284
Tau accumulation in patients with Alzheimer’s disease tracks closely with cognitive decline and plays a role in the later stages of disease progression. This phase 2 study evaluated the safety and efficacy of tilavonemab, an anti-tau monoclonal ant
Autor:
David Watson, Shau Yu Lynch, Hana Florian, Deli Wang, Sagar Bachhav, Joey Boiser, Anthony Bannon, Edwin Stage, Ole Graff
Publikováno v:
Tuesday, April 25.
Autor:
Wassilios G. Meissner, Roberto Eleopra, Taku Hatano, Francisco Grandas, Joseph F. Quinn, Justyna Sarna, Hui Zheng, Osamu Onodera, John T. Slevin, Theresa A. Zesiewicz, Anwar Ahmed, Erika Driver-Dunckley, Tao Xie, Hidek Mochizuki, Deborah A. Hall, John O`Sullivan, Peter A. Ljubenkov, Carlo Colosimo, Tomoko Oeda, Luc Defebvre, Diana R. Kerwin, Hana Florian, Deli Wang, Hoi-Kei Lon, David S. Geldmacher, Nahome Fisseha, Jennifer Hui, Elizabeth Peckham, Noriko Nishikawa, Jean-Christophe Corvol, Günter U. Höglinger, Jared Brosch, Fabienne Ory-Magne, Alberto Albanese, Kumar Budur, Yvette Bordelon, Zbigniew K. Wszolek, Stefano Ruggieri, Akio Kikuchi, James H. Bower, Kelly Bertram, Antonio Daniele, Daryl Wile, Ikuko Aiba, Rajeev Kumar, Lawrence S. Honig, Daniel Claassen, Victor S.C. Fung, Renato P. Munhoz, Beatrice Rendenbach-Mueller, Michael Gold, Ziyi Jin, Albert C. Ludolph, Nuno Mendonca, Ronald B. Postuma, John C. Morgan, Alexandre Eusebio, Aldo Quattrone, Antoine Duquette, Pablo Mir Rivera, Irene Litvan, Thomas E. Kimber, Michele Tagliati, Paola Cudia, Stefan Lorenzl, Takashi Kimura, Zoltan Mari, Hideki Oizumi, Nikolaus R. McFarland, Davis C. Ryman, Lawrence I. Golbe, Paul E Schulz
Publikováno v:
The lancet / Neurology 20(3), 182-192 (2021). doi:10.1016/S1474-4422(20)30489-0
Summary Background Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy
Autor:
Emily A, Largent, Sarah, Walter, Nancy, Childs, Penny A, Dacks, Shana, Dodge, Hana, Florian, Jonathan, Jackson, Jorge J, Llibre Guerra, Erin, Iturriaga, David S, Miller, Monica, Moreno, Rachel L, Nosheny, Thomas O, Obisesan, Elena, Portacolone, Bernadette, Siddiqi, Nina, Silverberg, Rueben C, Warren, Kathleen A, Welsh-Bohmer, Rebecca M, Edelmayer
Publikováno v:
Alzheimer'sdementia : the journal of the Alzheimer's AssociationREFERENCES.
Between 2018 and 2019, multiple clinical trials ended earlier than planned, resulting in calls to improve communication with and support for participants and their study partners ("dyads"). The multidisciplinary Participant Follow-Up Improvement in R
Autor:
Kimberly Crimin, Patricia J Allen, Iman Abba, Corinne Ahlberg, Luke Benz, Hiuyan Lau, Jingshu Liu, Fareed Melhem, Nahome Fisseha, Hana Florian
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
Dustin W. Wooten, Qi Guo, Ziyi Jin, Scott Gladstein, Edwin Stage, Jacob Hesterman, Nahome Fisseha, Hana Florian, Robert A. Comley
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
Scott Gladstein, Liuqing Yang, Dustin W Wooten, Hana Florian, Xin Huang, Robert A. Comley, Qi Guo
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
David M. Holtzman, Steven E. Arnold, Hana Florian, Deli Wang, Randall J. Bateman, Holly Soares, Joel B. Braunstein, Diana R. Kerwin, Kumar Budur
Publikováno v:
Alzheimer's & Dementia. 15